Exploiting loss of heterozygosity for allele-selective colorectal cancer chemotherapy

Journal: Nature Communications

Published: 2020-03-11

DOI: 10.1038/s41467-020-15111-4

Affiliations: 6

Authors: 14

Go to article
Institutions Share
Science for Life Laboratory (SciLifeLab), Sweden 0.46
Dana-Farber Cancer Institute (DFCI), United States of America (USA) 0.18
Chemical Biology Consortium Sweden (CBCS), Sweden 0.14
Temasek Life Sciences Laboratory (TLL), Singapore 0.14
Uppsala University Drug Optimization and Pharmaceutical Profiling Platform (UDOPP), UU, Sweden 0.07

Return

Except where otherwise noted © 2021 Springer Nature Limited. All Rights Reserved.
partner of AGORA, HINARI, OARE, INASP, ORCID, CrossRef and COUNTER